TGFB1 and breast carcinoma: In addition, treatment of TNBC xenografts with LY2157299, the TGF-β type I receptor kinase inhibitor, prevented relapse of tumors after paclitaxel treatment, suggesting that chemotherapy-induced TGF-β signaling enhances tumor recurrence and that TGF-β pathway inhibitors prevent the development of drug-resistant breast cancer cells [42].